PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents growing 13.37% while TRVN's declined -6.93%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of TRVN's -6.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of TRVN's -5.89%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
≥ 1.5x TRVN's -2.89%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of TRVN's 1.84%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of TRVN's -5.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Less than half of TRVN's 6.94%. David Dodd sees a more disciplined AP approach or lower volume.
2.29%
50-75% of TRVN's 3.17%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Below half of TRVN's 81.89%. Michael Burry suspects a big gap in pre-sales traction.
-2.29%
Exceeding 1.5x TRVN's -0.28%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-6.99%
Less than half of TRVN's 10.81%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Above 1.5x TRVN's -2.82%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Less than half of TRVN's 6.20%. David Dodd sees far fewer liability expansions relative to competitor.
10.53%
Above 1.5x TRVN's 2.48%. Michael Burry suspects heavy new equity expansion or dilution.
-2.12%
0.5-0.75x TRVN's -3.10%. Martin Whitman is wary of weaker retention or lower profitability.
-7.96%
Higher AOCI Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half TRVN's -7.71%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half TRVN's -5.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Above 1.5x TRVN's -2.23%. Michael Burry sees a major jump. Investigate leverage rationale.
-13.63%
Less than half of TRVN's 7.32%. David Dodd sees better deleveraging or stronger cash buildup than competitor.